Work

1840P RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC)

Year: 2023

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2788

Authors: J. Carmichael, I. Figueiredo, B. Gurel, W. Yuan, J. Rekowski, G. Seed, S. Carreira, C. Bertan, N. Beije, D. Westaby, C. Guo, A. Neeb, J. Welti, L. Gallagher, D. Bogdan, M. Crespo, R. Riiisneas, C. Lord, A. Sharp, J.S. de Bono

Institutions: Institute of Cancer Research, Royal Marsden Hospital

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Pfizer, AstraZeneca, Sanofi, Astellas Pharma, Medical Research Council

Award: G5773843864

OpenAlex ID: W4387810112

FWCI:

Cites:

Cited by:

Related to: 10